Ventilator-associated pneumonia: how long is long enough?

Area of Science:

• Infectious Diseases
• Critical Care Medicine
• Antimicrobial Stewardship

Background:

• Ventilator-associated pneumonia (VAP) is a leading ICU infection with significant morbidity and antimicrobial use.
• Prolonged antibiotic courses (10-14 days) were historically standard, especially for multidrug-resistant (MDR) or extensively drug-resistant (XDR) organisms.

Purpose of the Study:

• To provide an updated overview of optimal antibiotic duration for VAP.
• Integrate guideline recommendations, clinical evidence, and expert opinion on VAP treatment duration.

Main Methods:

• Review of guideline recommendations.
• Synthesis of clinical evidence from randomized controlled trials, retrospective studies, and meta-analyses.
• Inclusion of expert opinion on VAP management.

Main Results:

• Evidence supports shorter antibiotic regimens (≤7-8 days) for immunocompetent VAP patients, reducing toxicity and resistance without compromising outcomes.
• Recent trials with newer agents often exceed 7 days, reflecting challenges with resistant pathogens and trial design.
• Guideline convergence favors 7-8 day VAP therapy, with exceptions for specific pathogens, bacteremia, or slow clinical response.

Conclusions:

• Shorter antibiotic courses (≤7-8 days) are increasingly supported for VAP, emphasizing clinical response and individualization.
• Exceptions to shorter courses are necessary for specific pathogens (MDR/XDR organisms, nonfermenters), bacteremia, and structural lung disease.
• Further research is needed for immunocompromised patients and ultra-short VAP regimens, while biomarkers require VAP-specific validation.